Long-term safety follow-up for people treated with A2 Bio gene therapy products
Follows adults who received A2 Bio gene therapy for cancers, watching for late safety problems.
Key facts
- Who runs it
- A2 Biotherapeutics Inc.
- Where
- Gilbert, New York, and Rochester, United StatesSee the 3 sites
- Trial code
- Registry title
- A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products
- Status
- Enrolling by invitation
- People taking part
- 400 people, planned
- Started
- 31 Jul 2025
- Expected to end
- 31 Mar 2040
- Type of study
- Observational
- Treatments tested
- No additional intervention administered in this long term follow-up study
- Record updated
- 20 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who already received an A2 Bio gene therapy product in an earlier A2 Bio study. It follows them over the long term to watch for delayed safety problems.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Earlier treatment
- Must have received any amount of an A2 Bio gene therapy product in a previous A2 Bio interventional study.
Main reasons for not taking part
- The record lists no specific exclusion criteria.
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Received any amount of A2 Bio GT product on a previous A2 Bio interventional study
- Able to provide written informed consent for this long-term follow-up study
- Able to comply with study requirements
Who cannot take part
- There are no specific exclusion criteria for this study
Where in United States
- Banner HealthGilbert, United StatesEnrolling by invitation
- NYU Langone Medical CenterNew York, United StatesEnrolling by invitation
- Mayo ClinicRochester, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
This protocol is to ensure consistent long-term follow-up for delayed safety events in participants who received A2 Bio gene therapy (GT) products.
The group in the trial
- Participants that received A2 Bio GT products
Treatment: No additional intervention administered in this long term follow-up study
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2Bio) Gene Therapy (GT) Products
- Plain-language title
- Long-term safety follow-up for people treated with A2 Bio gene therapy productsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 20 May 2026